Wave claimed GSK is walking away from the frontrunning program not because of questions about its potential, but because Wave ...
Researchers showed that an RNA-based therapy targeting the SETBP1 mutation reduced the incidence of hydrocephalus in mice, ...
Hydrocephalus is a life-threatening condition that occurs in about 1 in 1,000 newborns and is often treated with invasive ...
After GSK’s return of Wave Life Sciences’ WVE-006 as well as the mid-stage failure of Korro Bio’s candidate, the alpha-1 ...
Investing.com -- Wave Life Sciences Ltd (NASDAQ:WVE) stock rose 2.1% Monday after the clinical-stage biotechnology company announced it has regained full rights to WVE-006, its investigational RNA ...
While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in ...
Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The "RNA Therapy Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ...
We recently published 10 Shares Explode as Earnings Impress. Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the best-performing stocks on Friday. Avidity Biosciences saw its share prices increase by ...
In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...
Hydrocephalus is a life-threatening condition that occurs in about 1 in 1,000 newborns and is often treated with invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results